Cycloset

Hyperprolactinemia, Acromegaly, Type 2 Diabetes + 2 more

Treatment

7 FDA approvals

20 Active Studies for Cycloset

Treatment for

Hyperprolactinemia

What is Cycloset

BromocriptineThe Generic name of this drug

Treatment SummaryBromocriptine mesylate is a medication used to treat symptoms of Parkinsonian Syndrome, a neurological disorder. It can also be used to reduce levels of the hormone prolactin in patients with too much of it in their system, and suppress growth hormone in people with acromegaly. There is a risk of developing pulmonary fibrosis when taking this drug.

Parlodelis the brand name

image of different drug pills on a surface

Cycloset Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Parlodel

Bromocriptine

1978

Approved as Treatment by the FDA

Bromocriptine, commonly known as Parlodel, is approved by the FDA for 7 uses like Parkinson's Disease (PD) and Type 2 Diabetes Mellitus .

Parkinson's Disease (PD)

Type 2 Diabetes Mellitus

Helps manage Type 2 Diabetes Mellitus

Hyperprolactinemia

Helps manage Hyperprolactinemia

Hyperprolactinemia

Helps manage Hyperprolactinemia

Type 2 Diabetes

Helps manage Type 2 Diabetes Mellitus

Parkinson's Disease

Acromegaly

Helps manage Acromegaly

Effectiveness

How Cycloset Affects PatientsBromocriptine works by activating certain dopamine receptors in the brain, which help reduce symptoms of movement disorders and improve dopamine activity. It also affects other receptor types, including serotonin receptors, alpha-2 adrenergic receptors, and dopamine D1 receptors. As a result, it can help treat Parkinson's syndrome by restoring dopamine activity in the brain. It can also help reduce prolactin secretion and has been linked to hallucinations and delusions (similar to those experienced by people with schizophrenia). Side effects related to bromocriptine may include pulmonary fibrosis due to its effects on some serotonin receptors.

How Cycloset works in the bodyThe dopamine D2 receptor is a protein that sits on the surface of cells and is linked to G proteins. When it is activated, it stops certain chemicals from entering the cell, which lowers the amount of calcium in the cell. It also blocks certain proteins from being activated, which helps stop the cell from growing and dividing. Finally, it helps to improve coordination in people with movement disorders by activating the same pathway in the part of the brain responsible for movement.

When to interrupt dosage

The suggested measure of Cycloset is contingent upon the diagnosed condition, including Hyperprolactinemia, Acromegaly and Parkinson's Disease. The dosage is dependent on the delivery approach (e.g. Oral or Capsule) as specified in the table beneath.

Condition

Dosage

Administration

Neuroleptic Malignant Syndrome

2.5 mg, , 5.0 mg, 0.8 mg

, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hyperprolactinemia

2.5 mg, , 5.0 mg, 0.8 mg

, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Acromegaly

2.5 mg, , 5.0 mg, 0.8 mg

, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Type 2 Diabetes

2.5 mg, , 5.0 mg, 0.8 mg

, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Parkinson's Disease

2.5 mg, , 5.0 mg, 0.8 mg

, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Warnings

Cycloset Contraindications

Condition

Risk Level

Notes

Acromegaly, Prolactinoma, Parkinson's Disease

Do Not Combine

Hypertensive disease

Do Not Combine

Coronary Artery Disease

Do Not Combine

Heart Disease

Do Not Combine

treatment withdrawal during pregnancy

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Cycloset.

Common Cycloset Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

Bromocriptine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine.

4-Methoxyamphetamine

Major

Bromocriptine may increase the hypertensive and vasoconstricting activities of 4-Methoxyamphetamine.

5-methoxy-N,N-dimethyltryptamine

Major

Bromocriptine may increase the vasoconstricting activities of 5-methoxy-N,N-dimethyltryptamine.

Abediterol

Major

Bromocriptine may increase the hypertensive and vasoconstricting activities of Abediterol.

Acepromazine

Major

Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Cycloset Toxicity & Overdose RiskOverdosing on Metoprolol can cause nausea, vomiting, and abnormally low blood pressure. Other common side effects include headaches, dizziness, constipation, feeling faint, abdominal pain, stuffy nose, diarrhea, and low blood pressure.

Cycloset Novel Uses: Which Conditions Have a Clinical Trial Featuring Cycloset?

Currently, 217 active trials are being conducted to determine the effectiveness of Cycloset in the management of Acromegaly, Hyperprolactinemia and Neuroleptic Malignant Syndrome (NMS).

Condition

Clinical Trials

Trial Phases

Parkinson's Disease

39 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1

Acromegaly

6 Actively Recruiting

Phase 2, Phase 3, Phase 1

Neuroleptic Malignant Syndrome

0 Actively Recruiting

Hyperprolactinemia

0 Actively Recruiting

Type 2 Diabetes

166 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Cycloset Reviews: What are patients saying about Cycloset?

5Patient Review

8/18/2011

Cycloset for Additional Medication for Diabetes Type 2

Not only has my sex drive increased since taking this medication, but I've also noticed a reduction in hot flashes and night sweats. Additionally, I believe that I have ADD and this medicine has allowed me to stay focused on one task at a time rather than becoming easily distracted.

5Patient Review

2/1/2011

Cycloset for Neuroleptic Malignant Syndrome

4.3Patient Review

7/17/2012

Cycloset for Additional Medication for Diabetes Type 2

I'm a 53 year old man with type 2 diabetes. I started taking Cycloset on 12/1/11 and had an episode of syncope (a brief loss of consciousness) and nausea. This was thought to be due to an interaction with Sudafed, so I reduced the dosage to 2 tablets per day without Sudafed. However, I had another episode of syncope and nausea on 2/5. My blood sugar was never improved with this medication, so I am discontinuing it immediately.

3.3Patient Review

11/10/2011

Cycloset for Additional Medication for Diabetes Type 2

This is a new drug, and so far I've seen good effects from it.

3.3Patient Review

9/22/2013

Cycloset for Additional Medication for Diabetes Type 2

I found that my blood pressure would drop after taking this medication, so be cautious if you have a similar condition.

2Patient Review

7/12/2014

Cycloset for Additional Medication for Diabetes Type 2

I was given this medication for Type 2 diabetes in an effort to lower my A1C. I had tried other medications before, but none of them worked. This one also made my FBS go higher, which is not what I needed.

1.7Patient Review

8/18/2013

Cycloset for Additional Medication for Diabetes Type 2

I did not have a good experience with this treatment. I felt awful while taking it and my blood sugar spiked pretty significantly. My feet also swelled up, which was new for me. Within a day of stopping the medication, I already felt so much better.

1Patient Review

11/16/2012

Cycloset for Additional Medication for Diabetes Type 2

Cycloset gave me awful flu-like symptoms that made my stomach hurt, constantly nauseous, and lethargic. I refused to take it after almost a year of this because my doctor switched me to Amryl, which is working great.

1Patient Review

4/15/2014

Cycloset for Additional Medication for Diabetes Type 2

I felt awful after taking this medication. I had a rapid heart rate, felt dizzy and weak, and just generally unwell.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cycloset

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is cycloset syrup used for periods?

"Cycloset bromocriptine is used to treat certain menstrual problems, like amenorrhea, in women. It also stops milk production in some men and women who have abnormal milk leakage. Lastly, it is used to treat infertility in both men and women that occurs because the body is making too much prolactin."

Answered by AI

How does cycloset work?

"As your blood sugar decreases, so does your risk for heart disease and other diabetes-related complications.

CYCLOSET helps control blood sugar by increasing insulin sensitivity in adults with type 2 diabetes. Insulin is the hormone your body produces to help change blood sugar into energy, and CYCLOSET helps lower blood sugar levels. As your blood sugar decreases, your risk for heart disease and other diabetes-related complications also decreases."

Answered by AI

What drug class is cycloset?

"Cycloset is a prescription medication used to treat the symptoms of Type 2 diabetes Mellitus. Cycloset may be used alone or with other medications. Cycloset belongs to a class of drugs called Dopamine Agonists, which are drugs that act on the dopamine system in the brain."

Answered by AI

What is cycloset used for?

"The drug CYCLOSET (bromocriptine mesylate) is indicated for use by adults with type 2 diabetes, in conjunction with diet and exercise, to lower blood sugar levels. CYCLOSET is not recommended for use by people with type 1 diabetes or by those with diabetic ketoacidosis."

Answered by AI

Clinical Trials for Cycloset

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25

All Sexes

Los Angeles, CA

The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.

Recruiting

Has No Placebo

University of California, Los AngelesLauren E Wisk, PhD

Have you considered Cycloset clinical trials? We made a collection of clinical trials featuring Cycloset, we think they might fit your search criteria.

Have you considered Cycloset clinical trials? We made a collection of clinical trials featuring Cycloset, we think they might fit your search criteria.